Results of an open, longitudinal multicenter LDL-apheresis trial

Transfusion Science

Volumn 20, Issue 1, 1999, Pages 83-94

  Borberg, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ANGINA PECTORIS; APHERESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GERMANY; HUMAN; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 0032904674     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00097-6     Document Type: Conference Paper

References (40)

1. Belák M, Widder RA, Brunner R, Borberg H, Haupt WF. Immunoadsorption with protein A sepharose or silica (letter). Lancet 1994;343:792-793.
2. Blankenhorn DH, Myers HI. Radiographic determination of Achilles tendon xanthoma size. Metabolism 1969;18: 882-886.
3. Borberg H, Stoffel W, Oette K. The development of specific plasmaimmunoadsorption. Plasma Ther Transfus Technol 1983;4(4):459-466.
4. Borberg H. The development of an automated therapeutic immunoadsorption system using the LDL-apheresis model. Eur J Clin Invest 1983;13:A39.
5. Borberg H, Gaczkowski A, Hombach V, Oette K, Stoffel W. Treatment of familial hypercholesterolaemia by means of specific immunoadsorption. J Clin Apheresis 1988;4:59-65.
6. Borberg H, Oette K. Experience with and conclusions from three trials on LDL-Apheresis. In: Agishi T. et al., editors. Therapeutic plasmapheresis (XII). VSP BV, Utrecht, 1993, p. 13-20.
7. Borberg H, Oette K. Outlooks in LDL-apheresis. In: Koenig W, Hombach V, Bond MG, Kramsch DM, editors. Progression and regression of atherosclerosis. Blackwell Wissenschaft, Wien, 1995, p. 306-318.
8. Borberg H. Extracorporeal elimination therapy of autoimmune diseases. In: Yamamoto A, Gurland HJ, editors. Current advances in haemapheresis. Churchill Livinstone, 1995, p. 83-93.
9. De Gennes JL, Toutaine R, Maunand B, Truffert J, Laudat P. Forme homozygotes cutaneo-tendineuses de xanthomatose hypercholesterolèmique dans une observation familiale exemplaire. Essai de plasmaphèrése a titre de traitement heroique. Bull. Mem. Soc. Hop. Paris 1967;118:1377-13402.
10. Freudenhammer, Ch. Untersuchungen zur Biokompatibilität der LDL-Apherese. Aktivierung von Monozyten und neutrophilen Granulozyten. Thesis, University of Köln, 1997.
11. Gupta S, Leatham EW. The relation between Clamydia pneumoniae and atherosclerosis. Brit Med J 1997;77:7-8.
12. Gdawitz, A, Nagel R, Degenhardt R, Borberg H, Schmid-Schönbein H. High resolution constant shear platelet aggregometry: effect of hyperlipidaemia and hae mapheretic treatment of hypercholesterolaemia Abstract, 14.Jahrestagg. Dtsch.Gesellsch. Klin. Mikrozirkulat. Haemorheol., Berlin, 1995.
13. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-1538.
14. Hombach V, Borberg H, Gaczkowski A, Oette K, Stoffel W. Regression der Koronarsklerose bei familiärer Hyperchoelsterinämie Typ IIa durch spezifische LDL-Apherese. Dtsch Med Wschr 1986;45:1709-1715.
15. Hummelsheim T, Borberg H, Brunner R, Oette K. Acute changes of haemorheological parameters by LDL-Apheresis: specific immunoadsorption versus cascade filtration. Infusionsther Transfusionsmed 1994;22 Suppl 1:42-44.
16. Jimenez-Klingberg C, Borberg H. Comparison of protein A and tryptophan conjugated polyvinyl-alcohol gel columns with an anti-human immunoglobulin adsorber. In: Yamamoto A, Gurland HJ, editors. Current advances in haemapheresis. Churchill Livinstone, 1995, p. 83-93.
17. Jimenez-Klingberg C, Borberg H, Belak M, Späth P. Selektive Adsorption von Kryoglobulinen aus dem Plasma von drei Patienten mit gemischterTyp II Kryoglobulinämie. Beitr Infusionsther Transfusionsmed 1994;32: 370-373.
18. Kadar JG, Späth PJ, Gaczkowski A, Oette K, Stoffel W, Borberg H. Biocompatibility studies on a clinically well tolerated extracorporeal system. Plasma Ther Transfus Technol 1988;8:307-318.
19. Kikkawa T, Yokoyama S, Hayashi R, Yamamoto A, Santini M, Kishino B. Specificity of various plasmapheresis techniques for the treatment of hypercholesterolaemia. In: Shiokawa Y, Inoue N, editors. Current practice in therapeutic plasmapheresis. Excerpta Medica, Amsterdam, 1985, p. 144-151.
20. Koga N, Nomura G, Yamagata Y, Takada S, Nishimura T, Sanada A, Kanaya S, Fujino T. Double filtration plasmapheresis of two cases of homozygous familial hypercholesterolemia. In: Oda T, editors. Therapeutic plasmapheesis III. Schattauer, Stuttgart, 1983, p. 109-112.
21. Koga N, Sato T, Kurashige Y, Nagano T, Hashizume K, Iwamoto H. Longterm effects of LDL-liposorption on coronary and carotid athersosclerosis in familial hypercholesterolaemia opatients. In: Yamamoto A, editor. Therapeutic plasmapheresis XVI. Jpn J Apheresis 1997, p. 63-68.
22. Kroon AA, Aengevaeren WRM, van der Werf T, Uijen GJH, Reiber HC, Bruschke AVG, Stahlenhof AFH. Liposorption atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-1835.
23. Leung WH. Beneficial effect of cholesterol lowering therapy on coronary endothelium-dependent rexation in hypercholesterolaemic patients. Lancet 1993;341:1496-1500.
24. Levine GN, Keany JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-521.
25. Minakata T, Fukasawa A, Fujiwara S. Treatment of familial hypercholesterolemia using double filtration leukapheresis. In: Oda T, editor. Therapeutic plasmapheesis III. Schattauer, Stuttgart, 1983, p. 109-112.
26. Oette K, Borberg H. Variables in regression of atherosclerosis in familial hypercholesterolaemic patients under longterm LDL-apheresis. Plasma Ther Transfus Technol 1988;9:17-23.
27. Parusel M. Untersuchungen zur Biokompatibilität der LDL-Apherese. Interaktionen zwischen der Anti-Apolio-protein-B IgG-Sepharose 4B Cl. dem Komplementsystem und den Blutzellen. Thesis, University of Köln, 1994.
28. Sacks FM, Rouleau JL, Moye LA, Pfeffer MA, Warnica JW, Arnold MO, Nash DT, Brown LE, Sestier F, Rutherford J, Davis BR, Hawkins CM, Braunwald E. Baseline characteristics in the cholesterol and recurrent events (CARE). Trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 1995;75:621-623.
29. Saikku P, Mattila K, Nieminen MS, Hutten JK, Leinonen M, Ekman MR, Makela PH, Valtona V. Serological evidence of an association of a novel Clamydia, TWAR, with chronic heart disease and acute myocardial infarction. Lancet 1988;ii:983-985.
30. Scandinavian Simvastation survival study (4S). Lancet 1994;344:1383-1389.
31. Schuff-Werner P. Untersuchungen zur hämorheologischen Wirksamkeit der LDL-Apherese. Habilitationsschrift, Universität Göttingen, 1989.
32. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D. The Help-apheresis multicenter study. Eur J Clin Invest 1994;24:724-732.
33. Shepherd J, Cobbe SM, Ford I, Isles CH, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention (WESCOP) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333: 1301-1307.
34. Stoffel W, Demant T. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. Proc Natl Acad Sci USA 1981;78:611-615.
35. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet II 1981:1005-1007.
36. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A. Regression of coronary atherosclerosis by combined liposorption and lipid lowering drug therapy in patients with familial hypercholesterolaemia. A multicenter study. Atherosclerosis 1992;95:1-13.
37. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE. Assessment of long-term plasma exchange for familial hypercholesteroaemia. Brit Heart J 1980;43:680-688.
38. Thompson GR, Miller P, Breslow JL. Improved survival of patients with homozygous familial hypercholesteroaemia treated by plasma exchange. Brit Med J 1985;291: 1671-1673.
39. Thompson GR, Maher VMG, Mattews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolaemia regression study. Lancet 1995;345:811-816.
40. Waidner T, Franzen D, Voelker W, Ritter M, Borberg H, Hombach V, Höpp HW, for the LDL-Apheresis Study Group. The effect of LDL-apheresis on progression of coronary artery disease in patients with familial hypercholesterolaemia. Results of a multicenter LDL-apheresis study. Clin Invest 1994;72:858-863.